Apogee Therapeutics logo

Apogee Therapeutics Share Price (NASDAQ: APGE)

$36.89

▲

-0.4

(-1.07%)

Live

Last updated on

Check the interactive Apogee Therapeutics Stock chart to analyse performance

Apogee Therapeutics Key Stats

Check Apogee Therapeutics key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close
$37.29
Open
$37.95
Market Capitalization
$2.2B
Today's Volume
$552.7K
Revenue TTM
$0.0
EBITDA
$-270.3M
Earnings Per Share (EPS)
$-4.14
Profit Margin
0.0%
Quarterly Earnings Growth YOY
0.0%
Return On Equity TTM
-34.12%

Stock Returns calculator for Apogee Therapeutics Stock including INR - Dollar returns

The Apogee Therapeutics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Apogee Therapeutics investment value today

Current value as on today

₹77,795

Returns

₹22,205

(-22.21%)

Returns from Apogee Therapeutics Stock

₹26,279 (-26.28%)

Dollar Returns*

₹4,073 (+4.07%)

Indian investors sentiment towards Apogee Therapeutics Stock

-98%

Period: Jul 19, 2025 to Aug 18, 2025. Change in 30 Days versus previous period

Search interest for Apogee Therapeutics Stock from India on INDmoney has decreased by -98% in the last 30 days, reflecting a downward trend in search activity.

Analyst Recommendation on Apogee Therapeutics Stock

Rating
Trend

Buy

    91%Buy

    8%Hold

    0%Sell

Based on 12 Wall street analysts offering stock ratings for Apogee Therapeutics(by analysts ranked 0 to 5 stars)

Apogee Therapeutics Share Price Target

What analysts predicted

Upside of 162.27%

Target:

$96.75

Current:

$36.89

Apogee Therapeutics share price target is $96.75, a slight Upside of 162.27% compared to current price of $36.89 as per analysts' prediction.

Apogee Therapeutics Technicals Summary

Sell

Neutral

Buy

Apogee Therapeutics is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Apogee Therapeutics Dividend announcements

  • Apogee Therapeutics Earnings

    Apogee Therapeutics’s price-to-earnings ratio stands at None

About Apogee Therapeutics

Apogee Therapeutics, Inc., a clinical stage biotechnology company, develops novel biologics for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other inflammatory and immunology indications. The company develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for the treatment of AD, which is in phase 2 clinical trials; and for the treatment of asthma and EoE which is in phase 1 clinical trial. It also develops APG279 that is in preclinical stage for the treatment of AD; APG990, an SQ extended half-life mAb for the treatment of AD; APG333, a human mAb against thymic stromal lymphopoietin for the treatment of asthma and COPD; and APG808, an SQ extended half-life mAb targeting IL-4Ra for the treatment of Type 2 allergic diseases. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.
Organization
Apogee Therapeutics
Employees
196
CEO
Dr. Michael Thomas Henderson M.D.
Industry
Miscellaneous

Key Management of Apogee Therapeutics

NameTitle
Dr. Michael Thomas Henderson M.D.
CEO & Director
Ms. Jane Pritchett V. Henderson
Chief Financial Officer
Dr. Carl Linden Dambkowski M.D.
Chief Medical Officer
Ms. Noel Kurdi
Vice President of Investor Relations
Mr. Matthew Batters J.D.
Chief Legal Officer & Corporate Secretary
Ms. Emily Cox
SVP & Head of People
Dr. Rebecca Dabora Ph.D.
Chief Development Officer
Ms. Wendy Aspden-Curran
Senior Vice President of Clinical Operations
Dr. Drew Badger Ph.D.
Senior VP and Head of Regulatory Affairs & Toxicology
Ms. Monica Forbes
Senior Vice President of Finance

Important FAQs about investing in APGE Stock from India :

What is Apogee Therapeutics share price today?

Apogee Therapeutics share price today is $36.89 as on . Apogee Therapeutics share today touched a day high of {{1_rba_end}} and a low of {{1_rba_st}}.

What is the 52 week high and 52 week low for Apogee Therapeutics share?

Apogee Therapeutics share touched a 52 week high of {{rba_end}} and a 52 week low of {{rba_st}}. Apogee Therapeutics stock price today, is trending at $36.89, lower by 41.91% versus the 52 week high.

How to invest in Apogee Therapeutics Stock (APGE) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Apogee Therapeutics on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Apogee Therapeutics Shares that will get you 0.0407 shares as per Apogee Therapeutics share price of $36.89 per share as on August 19, 2025 at 1:16 AM IST.

What is the minimum amount required to buy Apogee Therapeutics Stock (APGE) from India?

Indian investors can start investing in Apogee Therapeutics (APGE) shares with as little as ₹87.3775 or $1 (as of August 19, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹873.77 in Apogee Therapeutics stock (as per the Rupee-Dollar exchange rate as on August 19, 2025). Based on Apogee Therapeutics share’s latest price of $36.89 as on August 19, 2025 at 1:16 AM IST, you will get 0.2711 shares of Apogee Therapeutics. Learn more about fractional shares .

What are the returns that Apogee Therapeutics has given to Indian investors in the last 5 years?

Apogee Therapeutics stock has given 75.65% share price returns and 16.91% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your US Stock Investments?